Generic semaglutide could enter the market as patent protections evolve, potentially reducing costs by 70% to 90%
His approach is simple: treat the whole person, not just the symptom
If the FDA finalizes its April 30, 2026 proposal to exclude semaglutide and tirzepatide from the 503B Bulks List, large-scale 503B compounding of those medications would no longer be legally permissible
No, GLP-1 patches aren't regulated in the same way as prescription medications
According to NHS England, those eligible will have: a BMI of 40 or over (or 37.5 if from a minority ethnic background) and four out of five of the following conditions: type 2 diabetes, high blood pressure, heart and vascular disease, high cholesterol and obstructive sleep apnoea Get in touch Do you have a story suggestion for Northamptonshire